Full-Time

Sr Forecast Analyst

Confirmed live in the last 24 hours

Dexcom

Dexcom

5,001-10,000 employees

Develops continuous glucose monitoring systems

No salary listed

Senior

No H1B Sponsorship

Edinburgh, UK + 2 more

More locations: Camberley, UK | Frankfurt, Germany

Candidates must have the Right to Work in the UK. Sponsorship is not available for this role.

Category
Financial Planning and Analysis (FP&A)
Finance & Banking
Required Skills
Tableau
Excel/Numbers/Sheets
Requirements
  • A few years of professional experience in a Demand Planning or FP&A function
  • Advanced Excel skills to build logical models
  • Direct experience and understanding of Revenue Forecasting
  • Understanding of database structure and manipulation
  • Experience with Visualization Software, such as Tableau or similar
  • Proficient in verbal and written communication in English (German, Dutch or another language would be an advantage)
Responsibilities
  • Develop and integrate various commercial analytics to inform key forecast assumptions
  • Lead the short-term and long-term forecasts of both inline and upcoming products
  • Collaborate critically and coordinate with pricing, corporate and regional finance, corporate and regional sales, marketing, and operations
  • Model the impact of change and visualize its effects on all areas of the business
  • Present forecast assumptions and results to senior leadership
  • Provide forecasts to sales operations for IC goal setting and S&OP for manufacturing and planning
  • Partner effectively and collaborate with internal divisions to integrate key market dynamics into demand forecasts
  • Perform mid-quarter variance analysis to assess the accuracy of forecasts
  • Drive alignment with commercial leaders around the forecasting process
  • Contribute to the continuous improvement of forecasting processes and methodologies
Desired Qualifications
  • Experience with SQL would be an advantage
  • Proficiency in German, Dutch or another language would be an advantage

Dexcom develops and sells continuous glucose monitoring (CGM) systems designed to help individuals manage diabetes. The main product, the Dexcom G6 CGM System, provides users with real-time glucose readings, enabling better control of their condition. The system includes a sensor that is placed under the skin to measure glucose levels continuously, and the data is sent to a smartphone app for easy access. Dexcom differentiates itself from competitors by offering a user-friendly interface and advanced data analytics through its Dexcom CLARITY software, which helps users and healthcare providers make informed decisions based on glucose trends. The company's goal is to enhance the quality of life for diabetes patients by providing accurate and convenient glucose monitoring solutions.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1999

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA clearance of G7 system enhances Dexcom's market credibility.
  • Integration with telehealth services boosts patient engagement and adherence.
  • AI integration in CGM systems improves predictive analytics and patient outcomes.

What critics are saying

  • Competition from Abbott's FreeStyle Libre 3 may impact market share.
  • Data privacy concerns with third-party platform integrations could deter users.
  • Hiring 1000 skilled workers may strain resources and cause inefficiencies.

What makes Dexcom unique

  • Dexcom G7 offers a 15-day wear period, reducing sensor replacements.
  • Direct Apple Watch connectivity allows glucose monitoring without an iPhone.
  • Dexcom CLARITY app provides detailed glucose patterns and trends analysis.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Remote Work Options

Flexible Work Hours

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Our Health Needs
Apr 14th, 2025
Dexcom receives FDA clearance for G7 15 Day glucose monitoring system

In March, cardiometabolic digital diagnostics company Nanowear announced a licensing and data partnership with Dexcom to integrate glucose data from the Dexcom G7 into its SimpleSense nanotechnology-enabled wearable.

Hit Consultant
Apr 10th, 2025
Fda Clears Dexcom G7 15 Day Continuous Glucose Monitoring System

What You Should Know:– Dexcom, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for individuals over the age of 18 with diabetes.– The Dexcom G7 15 Day system boasts an overall Mean Absolute Relative Difference (MARD) of 8.0% and builds upon the proven performance of Dexcom CGM technology, which has been clinically demonstrated to lower A1C, reduce hyper- and hypoglycemia, and increase time in range.Dexcom G7 FeaturesThe Dexcom G7 15 Day system offers up to 15.5 days of wear allowing users to benefit from fewer monthly sensors and reduced monthly waste. The waterproof CGM system provides an overall MARD of 8.0%.Other key features of Dexcom G7 include:Apple Watch Connectivity: Direct sensor connection to Apple Watch, allowing users to view glucose numbers without their iPhone.Direct sensor connection to Apple Watch, allowing users to view glucose numbers without their iPhone. Automated Logging: Automated activity logging, simplified meal logging, and new medication logging to help users understand the impact of these factors on glucose levels.Automated activity logging, simplified meal logging, and new medication logging to help users understand the impact of these factors on glucose levels. 12-Hour Grace Period: A 12-hour grace period for sensor replacement, ensuring a smoother transition between sessions.A 12-hour grace period for sensor replacement, ensuring a smoother transition between sessions. Mobile App with Dexcom Clarity: An innovative and user-friendly mobile app with Dexcom Clarity integration for easy viewing of glucose patterns, trends, and statistics through interactive reports.An innovative and user-friendly mobile app with Dexcom Clarity integration for easy viewing of glucose patterns, trends, and statistics through interactive reports

wflqzhanghaoran
Mar 27th, 2025
Dexcom COO on 15-day glucose sensor, Type 2 coverage | MedTech Dive

Dexcom is preparing to launch a 15-day version of its G7 continuous glucose monitor, based on data presented Thursday at the Advanced Technologies & Treatments for Diabetes conference.

MPO Magazine
Mar 26th, 2025
Dexcom Names Masimo Exec Jon Coleman as CCO

Dexcom names Masimo exec Jon Coleman as CCO.

Galway Beo
Mar 22nd, 2025
Dexcom opening date hiring 1000 jobs as highly skilled workers wanted

Dexcom opening date hiring 1000 jobs as highly skilled workers wanted.